肿瘤细胞治疗研究
英文原题：Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment.
Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment.
尽管治疗取得进展，卵巢癌患者的五年生存率仍 < 50%。
与宫颈癌或乳腺癌相比，卵巢癌在女性中较少见，但恶性程度更高、结局更差。尽管治疗取得进步，卵巢癌患者5年生存率仍低于50%。随着免疫检查点抑制剂（ICI）近期发展，癌症免疫治疗受到更多关注。焦亡是一种高度促炎的细胞死亡方式，对连接先天免疫与适应性免疫至关重要，并参与肿瘤微环境（TME）内免疫调节。近期研究显示，焦亡可促进卵巢癌免疫治疗，包括CAR-T 细胞或ICI治疗。此外，炎症小体、多种信号通路和长链非编码RNA（lncRNA）均可影响卵巢癌中的焦亡。本文讨论焦亡如何影响卵巢癌发生发展及其TME，并总结可能靶向焦亡细胞死亡过程、可用于卵巢癌治疗的小分子药物。
Ovarian cancer is a less common tumor in women compared to cervical or breast cancer, however it is more malignant and has worse outcomes. Ovarian cancer patients still have a five-year survival rate < 50% despite advances in therapy. Due to recent developments in immune checkpoint inhibitors (ICIs), cancer immunotherapy has attracted increased interest. Pyroptosis is a highly inflammatory form of cell death, which is essential for bridging innate and adaptive immunity, and is involved in immune regulation within the tumor microenvironment (TME). Recent research has shown that pyroptosis can promote immunotherapy of ovarian cancer, including treatment with chimeric antigen receptor T-cells (CAR-T) or ICIs. Moreover, inflammasomes, various signaling pathways and lncRNAs can all affect pyroptosis in ovarian cancer. Here we discuss how pyroptosis affects the development and progression of ovarian cancer as well as the TME. We also provide a summary of small molecule drugs that could target pyroptotic cell death processes and may be useful in ovarian cancer therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
